Search results
Results from the WOW.Com Content Network
Chemotherapy-induced acral erythema, also known as palmar-plantar erythrodysesthesia or hand-foot syndrome is reddening, swelling, numbness and desquamation (skin sloughing or peeling) on palms of the hands and soles of the feet (and, occasionally, on the knees, elbows, and elsewhere) that can occur after chemotherapy in patients with cancer.
Generalized bullous fixed drug eruption (GBFDE) most commonly refers to a drug reaction in the erythema multiforme group. [3]: 129 These are uncommon reactions to medications, with an incidence of 0.4 to 1.2 per million person-years for toxic epidermal necrolysis and 1.2 to 6.0 per million person-years for Stevens–Johnson syndrome.
Some of the most severe and life-threatening examples of drug eruptions are erythema multiforme, Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), hypersensitivity vasculitis, drug induced hypersensitivity syndrome (DIHS), erythroderma and acute generalized exanthematous pustulosis (AGEP). [4]
Chemotherapy-induced acral erythema (palmoplantar erythrodysesthesia syndrome) Chemotherapy-induced hyperpigmentation; Drug-induced acne; Drug-induced angioedema; Drug-related gingival hyperplasia; Drug-induced lichenoid reaction (drug-induced lichen planus, lichenoid drug eruption) Drug-induced lupus erythematosus; Drug-induced nail changes
This page was last edited on 19 January 2024, at 04:21 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Chemotherapy-induced acral erythema; Chemotherapy-induced hyperpigmentation; D. Dilantin hypersensitivity syndrome; Drug rash with eosinophilia and systemic symptoms;
Altogether, I had treatment for seven months: six rounds of intense chemo and 25 rounds of radiation. Because I had such a severe case in such a late stage, I was given an extremely strong ...
Chemotherapy-induced hyperpigmentation is caused by many chemotherapeutic agents (especially the antibiotics bleomycin, and daunorubicin) and the alkylating agents (cyclophosphamide and busulfan). [ 1 ] : 132